Biopharma Boardroom speaks with Quentin Le Masne de Chermont, Head of Corporate Strategy and Business Development at Grünenthal Group, a...
Biopharma Boardroom speaks with Nadia Aelbrecht, Vice President, Head of Infectious Disease at QIAGEN, about rapid diagnostics, antimicrobial...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Symbiosis Pharmaceutical Services is entering a new phase of growth following a £26 million investment to expand its ...
As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
For emerging biopharma companies, speed, quality and scalability cannot be treated as separate priorities. As products progress t...
Scientific breakthroughs are advancing rapidly across complex biologics, cell and gene therapies, radiopharmaceuticals and ADCs, but translating th...
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of ther...
As advanced therapies move from development towards commercial scale, quality is becoming far more than a regulatory checkpoint. It is increasingly...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (su...
Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Ansa Biotechnologies, Inc., a trusted partner for DNA synthesis...
The development of cannabinoid and psychedelic medicines is entering a more evidence-driven phase, with clinical validation, safety, regulatory a...
At INTERPHEX, sustainability and supply chain performance emerged as important priorities for pharmaceutical packaging. John Jansen, Head of Global Marketi...
© 2026 Biopharma Boardroom. All Rights Reserved.
